Recent Updates in the Role of Bispecifics in Multiple Myeloma: Highlights from ASH 2022 and Beyond : Episode 5
Treatment Approaches in High-Risk Transplant-Eligible NDMM Based on MRD Negativity
The panel reviews possible treatment approaches for patients with high-risk NDMM, and how MRD negativity affects their decision making.
EP: 1.GRIFFIN Trial in Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Final Subgroup Analysis
EP: 2.Treatment Approaches in Transplant-Eligible NDMM
EP: 3.Upfront Stem Cell Transplant and Maintenance Therapy in Transplant-Eligible NDMM
EP: 4.Analysis of Patients with Transplant-Eligible NDMM with High-Risk Cytogenetic Abnormalities who Received Frontline Daratumumab-Based Quadruplet Therapy
Now Viewing
EP: 5.Treatment Approaches in High-Risk Transplant-Eligible NDMM Based on MRD Negativity
EP: 6.Planned Interim Analysis of the GMMG-Concept Trial in High-Risk NDMM
EP: 7.Comparing Quadruplet Combination Treatment Regimens in NDMM
EP: 8.Updated Analysis of the Phase 3 MAIA Study in Transplant-Ineligible Patients with NDMM
EP: 9.Clinical Assessment of Key Subgroups of the Phase 3 Maia Study in Transplant-Ineligible Patients with NDMM
EP: 10.IFM2020-05/Benefit: Isatuximab Plus Lenalidomide, Dexamethasone, and Bortezomib for Elderly Patients with Transplant-Ineligible NDMM
Recent Videos
![“Every patient [with multiple myeloma] should be offered CAR T before they’re offered a bispecific, with some rare exceptions,” said Barry Paul, MD.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F70a5f0fed7009863fe30cf0740cf32014ebaf5be-2974x1660.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30 "“Every patient [with multiple myeloma] should be offered CAR T before they’re offered a bispecific, with some rare exceptions,” said Barry Paul, MD.")
![“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F267879fc15a40ec8d3ed04d8ee9c1f044b49ee89-2990x1692.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30 "“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.")
Related Content
Navigating AE Management for Cellular Therapy Across Hematologic Cancers
Tiba Al Sagheer, PharmD, BCOP, BCACP;Rebecca Gonzalez, PharmD, BCOP, FASTCT;Syeda Saba Kareem PharmD, BCOP
August 11th 2025Podcast
A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.
